Precigen (NASDAQ:PGEN) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Precigen from a "strong sell" to a "hold"; the stock has a consensus rating of Hold from analysts with an average price target of $8.50 (4 Buys, 2 Holds, 1 Sell).
• PGEN opened at $3.42 and was down about 2.6%, trading within a 52‑week range of $1.11–$5.47, with a market cap of $1.21 billion and a negative P/E of -2.46.
• Director Randal J. Kirk sold 1,900,036 shares at an average $4.18 (~$7.94M), reducing his holding by 84.8%; company insiders collectively own 47.10% of the stock.

Precigen (NASDAQ:PGEN - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research report on Thursday, January 22nd. HC Wainwright boosted their target price on shares of Precigen from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, November 14th. Finally, Wall Street Zen cut shares of Precigen from a "hold" rating to a "sell" rating in a report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $8.50.

Precigen Stock Down 2.6%

PGEN stock opened at $3.42 on Tuesday. Precigen has a fifty-two week low of $1.11 and a fifty-two week high of $5.47. The business's 50-day moving average is $4.32 and its two-hundred day moving average is $4.06. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -2.46 and a beta of 1.10.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of Precigen stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $4.18, for a total transaction of $7,942,150.48. Following the transaction, the director directly owned 341,189 shares of the company's stock, valued at $1,426,170.02. The trade was a 84.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 47.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Precigen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Patient Capital Management LLC lifted its holdings in Precigen by 62.6% during the third quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company's stock valued at $87,056,000 after purchasing an additional 10,192,107 shares in the last quarter. Lansing Street Advisors purchased a new stake in shares of Precigen in the third quarter worth $1,800,000. Diametric Capital LP bought a new stake in shares of Precigen during the 2nd quarter valued at $476,000. NBC Securities Inc. bought a new stake in shares of Precigen during the 4th quarter valued at $38,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Precigen by 49.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,194 shares of the biotechnology company's stock valued at $72,000 after buying an additional 5,674 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.